Background
==========

Focal and systemic bone loss in rheumatoid arthritis (RA) involves several cytokines such as RANKL, which is secreted by both osteoblasts and activated lymphocytes, and TNF-α. Anti-TNF-α antibodies decrease articular inflammation and bone erosions, but the effect on bone remains to be elucidated. Osteoprotegerin (OPG) inhibits bone resorption.

Objective
=========

We conducted the study to evaluate the respective and combined effect of OPG and anti-TNF-α antibodies on inflammation and on bone remodelling.

Methods
=======

DBA/1 mice were immunized then treated at the onset of arthritis with OPG-Fc or anti-TNF-α antibodies or with both OPG-Fc + anti-TNF-α antibodies or saline; one group of mice remained untreated (naïve). Deoxypyridinoline changes (Δ D-Pyr) in urine, bone mineral density gain (Δ BMD) at the total body level, and histomorphometric parameters at the femur metaphysis were measured.

Results
=======

Anti-TNF-α antibodies but not OPG decreased clinical and histological scores (*P*\< 0.02 versus saline). Δ BMD was lower in saline-treated CIA mice than in naïve mice (*P*\< 0.01), suggesting the effect of inflammation on bone loss. OPG and anti-TNF-α antibodies increased ΔBMD compared with saline (*P*\< 0.001 and *P*\< 0.05, respectively). ΔD-Pyr decreased by 65% with OPG and by 7% with saline (*P*\< 0.001), but by 13% when mice were treated with TNF-α antibodies (NS). Compared with saline, OPG induced increased trabecular (Tb) bone volume (*P*\< 0.02), decreased Tb spacing (*P*\< 0.02) and decreased BFR/BS (*P*\< 0.01). In contrast, the anti-TNF-α antibody treated group showed no significant changes in Tb bone volume and Tb spacing compared with saline, but Tb thickness was greater (*P*\< 0.02), close to that in naïve mice, suggesting a protective effect on bone formation. There was no additive effect of OPG and anti-TNF-α antibodies on any parameter.

Conclusion
==========

Administration of OPG and anti-TNF-α antibodies prevented bone loss in CIA mice through distinct mechanisms involving inhibition of bone resorption and formation. Combinations of both treatments must be further investigated.
